In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
Poster 1 Pre-assessment

Before you view the poster session, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. What are your credentials?

MD/DO

Nurse

Other (please specify)

Question Title

* 2. What is your specialty?

Oncology

Hematology

Pediatrics

Primary Care/Family Medicine

Other (please specify)

Question Title

* 3. How confident are you in the management of patients with ALL in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 4. Which of the following best describes how asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) asparaginase erwinia chrysanthemi (ERW) are similar?

Neither product is prone to drug shortages

Neither product is approved for use in pediatric patients

Both are manufactured via recombinant DNA technology

Both can be administered intramuscularly

Question Title

* 5. SP is a 10-year-old male who developed a grade 3 hypersensitivity reaction after his 3rd dose of pegaspargase on COG protocol AALL0232 for high-risk ALL. The pharmacy is unable to obtain ERW due to drug shortage.

Which of the following is most appropriate for SP?

Administer ERW-rywn

Administer calaspargase pegol

Provide premedications and continue pegaspargase

Discontinue asparaginase

Question Title

* 6. Which of the following was observed in serum asparaginase activity in the phase 2/3 clinical trial that led to FDA-approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) in cohort 1a (25 mg/m2 IM on Monday, Wednesday, Friday)?

SAA levels > 0.4 IU/mL at 48 hours in more than 60% of patients

SAA levels > 0.1 IU/mL at 48 hours in more than 90% of patients

SAA levels > 0.4 IU/mL at 72 hours in more than 60% of patients

SAA levels > 0.1 IU/mL at 72 hours in more than 90% of patients

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 1 Pre-assessment***

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your specialty?

Question Title

* 3. How confident are you in the management of patients with ALL in your practice?

Question Title

* 4. Which of the following best describes how asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) asparaginase erwinia chrysanthemi (ERW) are similar?

Question Title

* 5. SP is a 10-year-old male who developed a grade 3 hypersensitivity reaction after his 3rd dose of pegaspargase on COG protocol AALL0232 for high-risk ALL. The pharmacy is unable to obtain ERW due to drug shortage. Which of the following is most appropriate for SP?

Question Title

* 6. Which of the following was observed in serum asparaginase activity in the phase 2/3 clinical trial that led to FDA-approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) in cohort 1a (25 mg/m2 IM on Monday, Wednesday, Friday)?

Question Title

* 7. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia
Poster 1 Pre-assessment

* 5. SP is a 10-year-old male who developed a grade 3 hypersensitivity reaction after his 3rd dose of pegaspargase on COG protocol AALL0232 for high-risk ALL. The pharmacy is unable to obtain ERW due to drug shortage.

Which of the following is most appropriate for SP?